Trial Profile
Safety of ASF 1057 cream 0.5% under long term use in the treatment of seborrhoeic dermatitis: A 12 month open label extension multi-centre phase III trial
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs ASF 1057 (Primary)
- Indications Seborrhoeic dermatitis
- Focus Adverse reactions; Registrational
- Sponsors Astion Pharma A/S
- 21 Sep 2022 This trial is completed at Finland Location, According to European Clinical Trials Database record.
- 02 Feb 2018 New trial record